Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism

Overview

Journal Int J Pediatr Endocrinol

Publisher Biomed Central

Specialty Pediatrics

Date 2009 Dec 4

PMID 19956747

Citations 23

Authors

Tasuku Saito

Seiji Fukumoto

Affiliations

Soon will be listed here.

Abstract

Derangements in serum phosphate level result in rickets/osteomalacia or ectopic calcification indicating that healthy people without these abnormalities maintain serum phosphate within certain ranges. These results indicate that there must be a regulatory mechanism of serum phosphate level. Fibroblast growth factor 23 (FGF23) was identified as the last member of FGF family. FGF23 is produced by bone and reduces serum phosphate level by suppressing phosphate reabsorption in proximal tubules and intestinal phosphate absorption through lowering 1,25-dihydroxyvitamin D level. It has been shown that excess and deficient actions of FGF23 result in hypophosphatemic rickets/osteomalacia and hyperphosphatemic tumoral calcinosis, respectively. These results indicate that FGF23 works as a hormone, and several disorders of phosphate metabolism can be viewed as endocrine diseases. It may become possible to treat patients with abnormal phosphate metabolism by pharmacologically modifying the activity of FGF23.

Citing Articles

Exploring endocrine FGFs - structures, functions and biomedical applications.

Phan P, Ternier G, Edirisinghe O, Kumar T Int J Biochem Mol Biol. 2024; 15(4):68-99.

PMID: 39309613 PMC: 11411148. DOI: 10.62347/PALK2137.

Vitamin D and Toxic Metals in Pregnancy - a Biological Perspective.

Fisher M, Weiler H, Kuiper J, Borghese M, Buckley J, Shutt R Curr Epidemiol Rep. 2024; 11(3):153-163.

PMID: 39156920 PMC: 11329583. DOI: 10.1007/s40471-024-00348-0.

Association of Fibroblast Growth Factor 23 with Blood Pressure in Primary Proteinuric Glomerulopathies.

Pfaff M, Denburg M, Meyers K, Brady T, Leonard M, Hoofnagle A Am J Nephrol. 2023; 55(2):187-195.

PMID: 38128487 PMC: 10987260. DOI: 10.1159/000535092.

Impact of X-Linked Hypophosphatemia on Muscle Symptoms.

Romagnoli C, Iantomasi T, Brandi M Genes (Basel). 2022; 13(12).

PMID: 36553684 PMC: 9778127. DOI: 10.3390/genes13122415.

Renal Contributions to Age-Related Changes in Mineral Metabolism.

Irsik D, Bollag W, Isales C JBMR Plus. 2021; 5(10):e10517.

PMID: 34693188 PMC: 8520061. DOI: 10.1002/jbm4.10517.

References

Itoh N, Ornitz D . Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004; 20(11):563-9. DOI: 10.1016/j.tig.2004.08.007. View

Feng J, Ward L, Liu S, Lu Y, Xie Y, Yuan B . Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38(11):1310-5. PMC: 1839871. DOI: 10.1038/ng1905. View

Schouten B, Doogue M, Soule S, Hunt P . Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009; 46(Pt 2):167-9. DOI: 10.1258/acb.2008.008151. View

Topaz O, Shurman D, Bergman R, Indelman M, Ratajczak P, Mizrachi M . Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004; 36(6):579-81. DOI: 10.1038/ng1358. View

Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T . Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87(11):4957-60. DOI: 10.1210/jc.2002-021105. View

Yamashita T, Yoshioka M, Itoh N . Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000; 277(2):494-8. DOI: 10.1006/bbrc.2000.3696. View

Imel E, Hui S, Econs M . FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007; 22(4):520-6. DOI: 10.1359/jbmr.070107. View

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt K . Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281(10):6120-3. PMC: 2637204. DOI: 10.1074/jbc.C500457200. View

Gupta A, Winer K, Econs M, Marx S, Collins M . FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab. 2004; 89(9):4489-92. DOI: 10.1210/jc.2004-0724. View

10.

Ichikawa S, Imel E, Kreiter M, Yu X, Mackenzie D, Sorenson A . A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest. 2007; 117(9):2684-91. PMC: 1940239. DOI: 10.1172/JCI31330. View

11.

Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N . Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009; 45(4):814-6. DOI: 10.1016/j.bone.2009.06.017. View

12.

Weber T, Liu S, Indridason O, Quarles L . Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003; 18(7):1227-34. DOI: 10.1359/jbmr.2003.18.7.1227. View

13.

Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T . Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab. 2007; 25(6):419-22. DOI: 10.1007/s00774-007-0779-3. View

14.

Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K . Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002; 143(8):3179-82. DOI: 10.1210/endo.143.8.8795. View

15.

Riminucci M, Collins M, Fedarko N, Cherman N, Corsi A, White K . FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003; 112(5):683-92. PMC: 182207. DOI: 10.1172/JCI18399. View

16.

Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I . Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009; 24(11):1879-88. DOI: 10.1359/jbmr.090509. View

17.

Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D . Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone. 2008; 42(6):1235-9. DOI: 10.1016/j.bone.2008.02.014. View

18.

Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N . A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab. 2005; 90(10):5523-7. DOI: 10.1210/jc.2005-0301. View

19.

. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet. 1995; 11(2):130-6. DOI: 10.1038/ng1095-130. View

20.

Topaz O, Indelman M, Chefetz I, Geiger D, Metzker A, Altschuler Y . A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet. 2006; 79(4):759-64. PMC: 1592555. DOI: 10.1086/508069. View